Holding
In Cephalon, Inc. v. Slayback Pharma Ltd. Liab. Co.,
the Federal Circuit summarily affirmed under Rule 36 the district
court's decision that all asserted claims of the asserted
patents are not invalid, and that Defendants infringed and induced
infringement. Cephalon, Inc. v. Slayback Pharma Ltd. Liab.
Co., 456 F. Supp. 3d 594 (D. Del. April 27, 2020),
aff'd, 856 Fed. App'x. 309 (Fed. Cir. Aug. 13,
2021), reh'g denied (Fed. Cir. Oct. 15,
2021).1
Background
Teva Pharmaceuticals Int'l GmbH, Cephalon, and Eagle
Pharmaceuticals sued Apotex, Fresenius Kabi USA, Mylan Labs., and
Slayback Pharma under the Hatch-Waxman Act, 35 U.S.C. §
271(e)(2)(A). Defendants had filed Abbreviated New Drug
Applications (“ANDAs”) to market generic versions of
Bendeka®. Bendeka®'s active ingredient is bendamustine
hydrochloride (referred to by the parties as bendamustine). The
patents at issue were U.S. Patent Nos. 9,265,831 (“the
'831 patent”), 9,572,797 (“the '797
patent”),